Erasca, Inc., a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ERAS-801 for the treatment of malignant glioma, which includes glioblastoma (GBM). ERAS-801 is an orally bioavailable, small-molecule EGFR inhibitor that exhibited substantial central nervous system (CNS) penetration in preclinical animal studies.
Erasca's technology is based on the research of UCSF professor Kevan Shokat, PhD.